Moreover, suppression of SLC1A5 by V9302 promotes the efficacy of anti-PD-1, making SLC1A5 a valuable prognostic biomarker and therapeutic target for glioblastoma [53]. The gene discussed is SLC1A5; the disease is glioblastoma.